PCSA — Processa Pharmaceuticals, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1533743 ·
Last close
$1.73
Market Cap
$4.84M
52W High
$8.88
52W Low
$1.04
ADV30
139,355
Next earnings
—
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -2,336,138 -3,265,494 2,069,562 196,325 2,386,903
Mar 2026 0 — -3,331,214 -3,377,179 4,520,974 1,691,043 1,980,093
Dec 2025 0 — -3,701,889 -3,358,938 7,813,567 5,536,955 2,236,253
Sep 2025 0 — -3,488,843 -3,436,573 7,584,576 6,308,420 1,750,978

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-11,971,522
Investing CF
$-1,164,000
Financing CF
$6,395,227
CapEx
—
Dividends Paid
—
Buybacks
$-320
EPS Diluted TTM
$-10.49
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-107,425,706
Inventory
—
Receivables
—
ST Investments
$472,003
EBIT TTM
$-12,858,084
Pretax Income TTM
$-13,438,184
Interest Exp TTM
—
Analysts
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -13,988,505 -13,563,834 7,813,567 2,236,253 5,577,314 -11,385,195
Dec 2024 0 -12,051,206 -11,850,118 3,229,289 1,533,118 1,696,171 -11,245,042
Dec 2023 0 -11,457,061 -11,121,520 5,786,643 797,484 4,989,159 -8,063,346
Dec 2022 0 -20,257,288 -27,424,229 8,619,851 1,149,110 7,470,741 -9,605,143

TTM Snapshot

Revenues TTM
$-104,662
NetIncome TTM
$-13,438,184
OpCashFlow TTM
—
Assets (Latest)
$2,069,562
Forward EPS
$-3.75

Peers — same industry

TickerNameMarket CapLastDaily %
CNSY CERENOME, INC. $4.78M $0.63 —
CDT CDT Equity Inc. $4.93M $0.36 —
PULM Pulmatrix, Inc. $5.00M $1.37 —
LTRN Lantern Pharma Inc. $4.67M $0.37 —
CMND Clearmind Medicine Inc. $5.13M $3.45 —

News headlines (Yahoo Finance, 1h cache)

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-11-05 13:00 · Yahoo
Processa Pharmaceuticals Announces Key Leadership Appointments
2026-11-04 13:00 · Yahoo
Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics
2026-10-29 12:00 · Yahoo
Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Financing to Advance BTK Inhibitor Pipeline
2026-07-29 14:33 · Yahoo
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREA
2026-07-29 11:30 · Yahoo
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
2026-01-12 14:15 · Yahoo
Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
2026-01-09 14:00 · Yahoo
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
2026-01-05 14:15 · Yahoo
Wall Street Set to Open Higher Thursday as Inflation Rises Less Than Expected; Jobless Claims Decline
2025-12-18 14:23 · Yahoo
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
2025-12-17 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.